What is Akebia Ther (AKBA) stock price today?

Akebia Ther (AKBA) currently trades at $1.36 per share. The stock has a market capitalization of $364.82M and a P/E ratio of —x.

Is AKBA stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Akebia Ther has a Smart Value Score of 31/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 5/9 and Altman Z-Score is -9.09.

What is Akebia Ther's revenue and earnings?

Akebia Ther has trailing twelve-month (TTM) revenue of $236.20M with profit margins of -2.26%. Earnings per share (EPS) is $-0.02.

Is Akebia Ther financially healthy?

Akebia Ther's Piotroski F-Score is 5/9 (moderate financial health). The Altman Z-Score of -9.09 places it in the distress.

AKBA

Akebia Ther

NASDAQ: AKBA · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC

$1.36

-4.23% today

Updated 2026-04-29

Market cap

$364.82M

P/E ratio

—

P/S ratio

1.55x

EPS (TTM)

$-0.02

Dividend yield

—

52W range

$1 – $4

Volume

2.7M

Market cap

$364.82M

P/E ratio

—

P/S ratio

1.55x

EPS (TTM)

$-0.02

Dividend yield

—

52W range

$1 – $4

Volume

2.7M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.7

Growth

4.5

Quality

3.0

Profitability

5.0

Valuation

C+

5/9

Piotroski F-Score

Moderate

-9.1

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$4.40

+223.53%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

1 Strong Buy4 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Free cash flow $30.97M — positive

+ Revenue growth 23.90% QoQ

Risks

- Altman Z -9.09 — distress zone

- Thin margins at -2.26%

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$292.48M	$194.62M	$160.18M	$236.20M	$236.20M
Net income	$-94.23M	$-51.92M	$-69.41M	$-5.34M	$-12.24M
EPS	—	—	—	—	$-0.02
Free cash flow	$-73.27M	$-23.38M	$-40.69M	$67.70M	$30.97M
Profit margin	-32.22%	-26.68%	-43.33%	-2.26%	-2.26%

Recent insider activity

Date	Insider	Type	Shares	Price
2026-03-04	BUTLER, JOHN P.	Buy	69,270	$1.25
2026-02-02	RUCCI, CAROLYN M.	Sale	27,544	$1.39
2026-02-02	RUCCI, CAROLYN M.	Sale	25,382	$1.39

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
AKBA	$364.82M	31	4.7	3.0	5.0	4.5	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Akebia Ther trades at $1.36. Our Smart Value Score of 31/100 indicates the stock is weak. The company scores 5/9 on the Piotroski F-Score. With an Altman Z-Score of -9.09, it sits in the distress. TTM revenue stands at $236.20M. with profit margins at -2.26%.

Frequently asked questions

What is Akebia Ther's stock price?

Akebia Ther (AKBA) trades at $1.36.

Is Akebia Ther overvalued?

Smart Value Score 31/100 (Grade F, Strong Sell).

What is the price target of Akebia Ther (AKBA)?

The analyst target price is $4.40, representing +223.5% upside from the current price of $1.36.

What is Akebia Ther's revenue?

TTM revenue is $236.20M.

Piotroski F-Score?

5/9 — moderate financial health.

Altman Z-Score?

-9.09 — distress.

Company info

SectorHEALTHCARE

IndustryDRUG MANUFACTURERS - SPECIALTY & GENERIC

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio1.55x

ROE-553.00%

Beta0.37

50D MA$1.37

200D MA$2.13

Shares out0.27B

Float0.26B

Short ratio—

Avg volume2.7M

Performance

1 week-3.57%

1 month-4.93%

3 months-0.74%

YTD-16.15%

1 year—

3 years—

5 years—

Compare

AKBA vs LLY →AKBA vs JNJ →AKBA vs ABBV →Stock screener →